All In Biotech

Drug Trial Radar · NCT04049760

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

A Long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants

Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

16

Actual

Start

Oct 11, 2019

Primary completion

Nov 29, 2024

Study completion Nov 29, 2024

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects \> 12 Years of Age With Fabry Disease and Amenable GLA Variants

Conditions

  • Fabry Disease

Interventions

  • migalastat HCl 150 mgDrug

    migalastat HCl 150 mg capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study DrugTime frame: Entire study

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • University of South Florida

    Tampa, Florida

  • The Emory Clinic

    Atlanta, Georgia

  • University of Minnesota Masonic Children's Hospital and Clinics

    Minneapolis, Minnesota

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Lysosomal & Rare Disorders Research & Treatment Center

    Fairfax, Virginia

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.